Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy

Authors:
  • LBL. A. Byers
    L. A. Byers
  • MKM. S. Kies
    M. S. Kies
  • WWW. N. William
    W. N. William
  • JHJ. Hu
    J. Hu
  • JLJ. J. Lee
    J. J. Lee
  • AEA. El-Naggar
    A. El-Naggar
  • VPV. Papadimitrakopoulou
    V. Papadimitrakopoulou
  • JMJ. N. Myers
    J. N. Myers
  • SLS. M. Lippman
    S. M. Lippman
  • JHJ. V. Heymach
    J. V. Heymach

Abstract
6005 Background: 36 cytokines and angiogenic factors (C/AFs) were measured in HN patients on a Phase II induction chemotherapy trial to investigate connections between biomarker signatures and clinical outcomes. Methods: Previously untreated patients (n=47) received 6 weekly cycles of paclitaxel (135 mg/m2), carboplatin (AUC 2), and cetuximab (400 mg/m2 week 1; 250 mg/m2 weeks 2–6) followed by definitive local therapy. Eligible patients were stage T0–4, N2b/c/3, M0; PS 0–1; with any HN primary site. There were 12 complete and 34 partial responses (MS Kies, et al, 2006 ASCO Annual Meeting). Serum from 32 patients at baseline and after cycles 1 and 6 was analyzed in duplicate by multiplex bead assay. IGF-1 was quantified by ELISA. Factors that did not meet predetermined criteria were excluded or retested. Statistical analysis was performed to compare biomarkers between patients and time points. Results: Minimum follow-up was 2 years; 6 patients recurred. Unsupervised hierarchical clustering of baseline levels for 36 C/AFs identified two distinct patient subgroups. One subgroup (n=19) included all recurrences and was characterized by high levels of hypoxia-induced factors (ex., VEGF, IL-4, PDGF, IFN-α). Log-rank comparison of progression-free survival between subgroups had a p-value of 0.042. Patients who recurred had lower baseline IGF-1 (p=0.018) and higher GRO-α (p=0.033) by analysis of variance (ANOVA); they also differed in the degree to which IGF-1, NGF, and IL-7 (pp=0.05- 0.10) changed from pre- to post-treatment (by ordinary two-sample t-test). From the 10 C/AFs that changed most significantly (p≤0.01) across all patients following treatment, 6 biomarkers (IL-12, IL-18, CTACK, SDF-1α, G-CSF, and MPC-1) were selected as a classifier whose baseline levels predict recurrence by the stepwise (backward) model selection procedure based on Akaike's information criterion. Conclusions: C/AF profiling identified differences in circulating proteins in HN patients who relapsed. Immunohistochemical staining is being performed to compare levels of tumor proteins in related pathways. C/AF signatures will be validated in an independent patient cohort.